hackint0sh/New-Dataset huggingface dataset:
nctId: NCT06280560 id: 2109-FIVI-087-FD id: PI23/00860 type: OTHER_GRANT domain: Instituto de Salud Carlos III, co-funded by European Union briefTitle: Impact of IVF Hormonal Therapy on Endometrial Receptivity and Endometrial Senescent Cell Pathological Accumulation acronym: HormoSenoRec overallStatus: RECRUITING date: 2024-02-01 date: 2024-06-30 date: 2024-06-30 date: 2024-02-28 date: 2024-02-28 name: Fundación IVI class: OTHER name: Instituto Valenciano de Infertilidad, IVI VALENCIA briefSummary: Both controlled ovarian stimulation (COS) and frozen embryo transfer has become an integral part of in vitro fertilization (IVF) treatment. Fresh embryo transfer is usually performed by providing Luteal Phase Support (LPS) with progesterone after COS. Frozen embryo transfer (FET) is usually performed in artificial cycles with hormone replacement treatment (HRT), in which exogenous progesterone is administered, although it can also be performed in a Natural Cycle (without hormone supplementation) (NC). There is evidence that the supraphysiologic levels of estradiol and progesterone during COS+LPS and HRT could lead to morphologic and biochemical endometrial modifications, altering endometrial receptivity and lowering implantation and pregnancy rates.
We hypothesize that the supraphysiologic hormone levels required for both COS+LPS, and HRT may be inducing alterations in endometrial composition and function, specifically the chronic accumulation of senescent cells; either due to an excessive hormonal induction, a lack of clearance due to a deficit of uNKs, or a combination of both, ultimately affecting both endometrial receptivity and decidualization, worsening IVF outcomes.
The results derived from this project would have a direct impact on clinical practice. First, the results would allow us to evaluate, based on experimental data, potential endometrial side effects of stimulation protocols commonly used in IVF treatments. In addition, in the case of finding a pathological accumulation of senescent cells affecting endometrial receptivity, we will be able to in vitro evaluate the effectiveness of adjuvant senolytic (drugs designed to specifically remove senescent cells) compounds to in vitro improve the expression of endometrial receptivity markers, as a first step to demonstrate the effectiveness of their use in improving the reproductive outcomes of IVF patients. conditions: Endometrial Receptivity studyType: OBSERVATIONAL observationalModel: CASE_CONTROL timePerspective: PROSPECTIVE count: 60 type: ESTIMATED name: Controlled Ovarian Stimulation + Luteal Phase Support name: Hormonal Replacement Therapy programmed artificial cycle name: Natural Cycle (NC) name: Endometrial receptivity reference group measure: Endometrial receptivity measure: Senescent Cell Pathological Accumulation sex: FEMALE minimumAge: 18 Years maximumAge: 45 Years stdAges: ADULT facility: IVI-RMA Valencia Clinic status: RECRUITING city: Valencia zip: 46015 country: Spain name: Laura Caracena, PhD role: CONTACT phone: 651791000 email: Laura.Caracena@ivirma.com lat: 39.46975 lon: -0.37739 hasResults: False
nctId: NCT06280547 id: CUP 13-2 id: Cairo university type: OTHER domain: Cairo University briefTitle: The Effect of Oral Health Education on Knowledge, Attitude, Practice and Dental Caries Among Egyptian School Children acronym: KAP overallStatus: NOT_YET_RECRUITING date: 2024-02-29 date: 2024-03-02 date: 2024-04-02 date: 2024-02-28 date: 2024-02-28 name: Cairo University class: OTHER briefSummary: Aim of the study Assessing the effect of an oral health education program on knowledge, attitude, practice, and dental caries among a group of school children in a governmental school in Fayoum, Egypt. conditions: Dental Caries in Children conditions: Knowledge, Attitudes, Practice studyType: OBSERVATIONAL observationalModel: OTHER timePerspective: OTHER count: 115 type: ESTIMATED name: Oral health education measure: Oral health related attitude measure: Change in oral health related Knowledge, attitude and practice measure: Caries experience sex: ALL minimumAge: 6 Years maximumAge: 15 Years stdAges: CHILD hasResults: False
nctId: NCT06280534 id: XT1061-2022-01 briefTitle: Safety, Tolerability Phase Ia Study of XT1061 in Single and Multiple Doses in Healthy Subjects acronym: XT1061 overallStatus: RECRUITING date: 2023-07-18 date: 2024-02-29 date: 2024-03-31 date: 2024-02-28 date: 2024-02-28 name: Xi'an Xintong Pharmaceutical Research Co.,Ltd. class: OTHER briefSummary: A Randomized, Double-Blind, Single-Center Phase Ia Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Food Effects of Single and Multiple Doses of XT1061 in Healthy Subjects. conditions: Chronic Hepatitis b studyType: INTERVENTIONAL phases: PHASE1 allocation: RANDOMIZED interventionModel: SEQUENTIAL primaryPurpose: TREATMENT masking: DOUBLE whoMasked: PARTICIPANT whoMasked: OUTCOMES_ASSESSOR count: 128 type: ESTIMATED name: Test drug XT1061 capsules and placebo,Single dose group name: Test drug XT1061 capsules and placebo，Multiple dosing group name: Test drug XT1061 capsules and placebo，Food Impact Group measure: Treatment-related adverse events measure: Cmax measure: Tmax measure: t1/2 measure: AUC measure: CL/F measure: Vz/F measure: CLr/F measure: Ae0-72 h measure: Fe0-72 h measure: bioavailability sex: ALL minimumAge: 18 Years maximumAge: 65 Years stdAges: ADULT stdAges: OLDER_ADULT facility: The First Hospital of Jilin University status: RECRUITING city: Jilin state: Changchun country: China name: Ding Yanhua, master role: CONTACT phone: 18743062721 email: 1023307193@qq.com lat: 43.85083 lon: 126.56028 hasResults: False
nctId: NCT06280521 id: 38RC23.0331 briefTitle: Validation of the Girls Questionnaire for Autism Spectrum Condition in French Langage acronym: fGQ-ASC overallStatus: NOT_YET_RECRUITING date: 2024-04 date: 2026-04 date: 2026-05 date: 2024-02-28 date: 2024-02-28 name: University Hospital, Grenoble class: OTHER briefSummary: Autism spectrum disorders (ASD) are currently diagnosed at a rate of approximately 3 males per 1 female, while evidence suggests the rate may be 1.8 males per 1.2 females. It has been shown that affected women receive an autism diagnosis on average 5 years later than men. This delay is associated with deleterious consequences on the educational, psychological and physical health levels in these women. Currently, there are a number of obstacles that delay or prevent women with ASD from accessing diagnosis and specialized support. These include, in particular, gendered assumptions about how ASD manifests depending on the gender of the person concerned, a tendency for clinicians to attribute female autistic traits to causes other than ASD, measures of standardized ASD assessments that may not be sensitive enough to identify ASD females, and finally a demonstrated greater tendency among ASD females to camouflage or mask autistic traits in order to blend in in social situations. It is in this context that the Girl Questionnaire for Autism Spectrum Conditions (GQ-ASC) was developped and validated to address these fundamental gaps in the early identification and measurement of female ASD symptoms.
The main objective of this online study is therefore to measure the predictive validity of the French version of the Girl Questionnaire for Autism Spectrum Conditions (fGQ-ASC) for the diagnosis of ASD in adult women over 18 years of age and speaking French kindergarten. Subjects included in this online study will complete the protocol using any computer, tablet, or cell phone. We will include 400 participants (100 females-ASD, 100 females-nonASD, 100 males-ASD, 100 males-nonASD). This study will validate for the first time a screening tool for the diagnosis of ASD in women of French mother tongue over 18 years of age (the Girls Questionnaire for Autism Spectrum Condition French version - fGQ-ASC). This tool will have particularly significant benefits since it will help reduce the diagnostic delay among adult women with ASD in France and accelerate their access to specialized support. conditions: Autism Spectrum Disorder studyType: INTERVENTIONAL phases: NA allocation: NON_RANDOMIZED interventionModel: PARALLEL primaryPurpose: DIAGNOSTIC masking: NONE count: 400 type: ESTIMATED name: fGQ-ASC measure: VP fGQ-ASC sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
nctId: NCT06280508 id: SYSKY-2024-082-01 briefTitle: Chemotherapy Combined With Adebrelimab and Apatinib as the Perioperative Treatment in Patients With Biliary Tract Cancer overallStatus: RECRUITING date: 2024-03-01 date: 2027-03-31 date: 2028-03-31 date: 2024-02-28 date: 2024-04-23 name: Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University class: OTHER briefSummary: This is a prospective, single-arm exploratory study to evaluate the efficacy and safety of chemotherapy combined with Adebrelimab and Apatinib as the perioperative treatment in Patients With Biliary Tract Cancer. conditions: Resectable Intrahepatic Cholangiocarcinoma With High Risk of Recurrence studyType: INTERVENTIONAL phases: PHASE2 allocation: NA interventionModel: SINGLE_GROUP primaryPurpose: TREATMENT masking: NONE count: 40 type: ESTIMATED name: Adebrelimab, Apatinib, Gemcitabine, cisplatin measure: 1-year EFS rate measure: R0 Resection rate measure: EFS measure: RFS measure: OS sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University status: RECRUITING city: Guangzhou state: China/Guangdong country: China name: Yajin Chen role: CONTACT phone: 13719006202 email: cyj0509@126.com name: Changzhen Shang role: CONTACT phone: 13711279678 email: shangchangzhen@139.com lat: 23.11667 lon: 113.25 hasResults: False
nctId: NCT06280495 id: INTENSIFY-CRC briefTitle: Neoadjuvant Serplulimab & Bevacizumab With FOLFOX vs. FOLFOX Alone in RAS/BRAF WT, pMMR/MSS CRC Patients overallStatus: RECRUITING date: 2024-02-01 date: 2026-12-31 date: 2028-12-31 date: 2024-02-28 date: 2024-03-04 name: Sun Yat-sen University class: OTHER briefSummary: The primary objective of this study is to assess whether the addition of Serplulimab (a PD-1 inhibitor) and Bevacizumab (an anti-angiogenesis agent) to the standard FOLFOX chemotherapy can enhance the immune microenvironment in the liver, increase T lymphocyte infiltration, and consequently improve the postoperative prognosis for patients with surgically resectable colorectal cancer liver metastases (RAS/BRAF wild-type, pMMR/MSS) compared to FOLFOX alone. conditions: Colorectal Cancer conditions: Liver Metastases studyType: INTERVENTIONAL phases: PHASE2 phases: PHASE3 allocation: RANDOMIZED interventionModel: PARALLEL interventionModelDescription: This is a prospective, randomized, multicenter clinical trial. Stratified randomization based on liver metastasis characteristics, including timing, number, and size, will be conducted in eligible patients. primaryPurpose: TREATMENT masking: NONE count: 156 type: ESTIMATED name: Oxaliplatin name: Fluorouracil name: Serplulimab name: Bevacizumab measure: 3-year Progression-Free Survival Rate measure: Median Overall Survival measure: Major Pathological Response (MPR) measure: Pathologic complete response (pCR) measure: Pathological Partial Response measure: Disease Free Survival measure: Treatment-related adverse events sex: ALL minimumAge: 18 Years maximumAge: 75 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Sun Yat-sen University Cancer Center status: RECRUITING city: Guangzhou state: Guangdong zip: 510060 country: China name: Yu-hong Li, MD, Ph D role: CONTACT email: liyh@sysucc.org.cn name: Yu-hong Li, MD, Ph D role: PRINCIPAL_INVESTIGATOR lat: 23.11667 lon: 113.25 hasResults: False
nctId: NCT06280482 id: HSC-MS-23-0332 briefTitle: Nicotinamide Riboside (NR) to Treat Moyamoya-like Cerebrovascular Disease in Smooth Muscle Dysfunction Syndrome (SMDS) overallStatus: RECRUITING date: 2024-03-06 date: 2025-07-25 date: 2025-07-25 date: 2024-02-28 date: 2024-04-05 name: The University of Texas Health Science Center, Houston class: OTHER briefSummary: The purpose of this study is to determine whether SMDS patients treated with NR at the proposed dose exhibit decreased glucose uptake in the aorta, to determine if NR treatment results in measurable changes of blood NAD+ and NR levels, to determine if aortic measurements are stable after treatment with NR and to evaluate the safety and tolerability of NR in SMDS patients. conditions: Smooth Muscle Dysfunction Syndrome (SMDS) studyType: INTERVENTIONAL phases: PHASE1 allocation: NA interventionModel: SINGLE_GROUP primaryPurpose: TREATMENT masking: NONE count: 5 type: ESTIMATED name: Nicotinamide riboside (NR) measure: Change in Fluoro-18-Deoxyglucose (18F-FDG ) uptake in aortic wall as measured by positron emission tomography (PET)/computerized tomography (CT) imaging measure: Change in Levels of Nicotinamide adenine dinucleotide (NAD+) in whole blood as measured by high-performance liquid chromatography (HPLC) measure: Change in Levels of NR in whole blood as measured by high-performance liquid chromatography (HPLC) measure: Change in aortic measurements as assessed by echocardiography measure: Safety as assessed by number of participants that show drug toxicity as shown in bloodwork measure: Safety as assessed by number of participants that show drug toxicity as shown in bloodwork measure: Tolerability as assessed by the number of patients who complete study sex: ALL minimumAge: 5 Years maximumAge: 18 Years stdAges: CHILD stdAges: ADULT facility: The University of Texas Health Science Center at Houston status: RECRUITING city: Houston state: Texas zip: 77030 country: United States name: David Murdock, MD role: CONTACT phone: 713-500-6735 email: David.R.Murdock@uth.tmc.edu name: Dianna Milewicz, MD, PhD role: CONTACT phone: (713) 500-6725 email: Dianna.M.Milewicz@uth.tmc.edu lat: 29.76328 lon: -95.36327 hasResults: False
nctId: NCT06280469 id: KY20232298-C-1 briefTitle: Single-operator Versus Double-operator in Single-Balloon Enteroscopy acronym: SBE overallStatus: RECRUITING date: 2024-01-01 date: 2025-12 date: 2025-12 date: 2024-02-28 date: 2024-02-28 name: Shuhui Liang class: OTHER briefSummary: Compared with two-person in single-balloon enteroscopy, one-person single-balloon enteroscopy has the advantages of better observation and treatment of lesions, shorter examination time, saving resources in the endoscopy room, and reducing the postoperative discomfort of the examined person, etc. However, there is no comparative study of one-person and two-person in single-balloon enteroscopy. conditions: Single-balloon Enteroscopy conditions: Operation studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: DIAGNOSTIC masking: SINGLE whoMasked: PARTICIPANT count: 80 type: ESTIMATED name: Single-Balloon Enteroscopy measure: Maximum insertion depth measure: Total enteroscopy rate measure: Positive findings measure: Advent events measure: procedural time sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Xijing Hospital of Digestive Diseases status: RECRUITING city: Xi'an country: China name: Shuhui Liang role: CONTACT phone: +862084771536 email: liangsh@fmmu.edu.cn lat: 34.25833 lon: 108.92861 hasResults: False
nctId: NCT06280456 id: 2023-09-017A briefTitle: Tranexamic Acid Injection With Different Drainage Clamping Time After Anterior Cruciate Ligament Reconstruction overallStatus: COMPLETED date: 2022-09-05 date: 2023-01-05 date: 2023-02-05 date: 2024-02-28 date: 2024-02-28 name: Taipei Veterans General Hospital, Taiwan class: OTHER_GOV briefSummary: Post-anterior cruciate ligament reconstruction (ACLR) hemarthrosis may result in increased pain thus delaying postoperative rehabilitation, which may eventually lead to arthrofibrosis and a functional deficit. Many antifibrinolytic agents, including tranexamic acid (TXA), have been used in orthopedic surgeries to reduce postoperative bleeding. Moreover, TXA was proved effective to reduced the events of hemarthrosis and increased the post-operative functional outcomes of the patients in several studies. The purpose of this study is to evaluate the efficacy of intra-articular injection of TXA with different drainage clamping time in patients receiving arthroscopic ACLRs. Patients were randomized into four groups. An intra-articular suction drain was placed recorded 24 h postoperatively. Group 1 patients(TXA 4hr group) received the index procedures with a 10 mL intra-articular injection of TXA and following drainage clamped 4 hours. Group 2 patients(TXA 8hr group) received the index procedures with a 10 mL intra-articular injection of TXA and following drainage clamped 8 hours. Clinical evaluations using an IKDC functional score and a Visual Analogue Scale (VAS) pain score were performed during admission, at postoperative day 3 and week 4. conditions: Anterior Cruciate Ligament Reconstruction conditions: Tranexamic Acid conditions: Hemarthrosis, Knee studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: SINGLE_GROUP primaryPurpose: TREATMENT masking: SINGLE whoMasked: OUTCOMES_ASSESSOR count: 150 type: ACTUAL name: Tranexamic Acid Powder measure: The volume of drainage measure: Visual analog scale (VAS) measure: International Knee Documentation Committee (IKDC) functional score sex: ALL minimumAge: 20 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Taipei Veterans General Hospital city: Taipei country: Taiwan lat: 25.04776 lon: 121.53185 hasResults: False
nctId: NCT06280443 id: CE22407B briefTitle: Sarcopenia in Chronic Lung Diseases overallStatus: RECRUITING date: 2022-11-25 date: 2024-10-13 date: 2032-09-30 date: 2024-02-28 date: 2024-04-04 name: Taichung Veterans General Hospital class: OTHER briefSummary: Inclusion criteria A)Outpatients with COPD (chronic obstructive pulmonary disease) or ILD (interstitial lung disease) from department of Chest medicine in Taichung Veterans General Hospital, judged by the doctor that they do not need hospitalization or emergent treatment.
B) Patients who agree to provide the ID card number to the research team for usage as a link to the National Health Insurance research database and Health bank to explore the continuity of care and the use of medical resources conditions: Sarcopenia conditions: COPD conditions: Asthma conditions: ILD studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: PROSPECTIVE count: 300 type: ESTIMATED measure: sarcopenia rate sex: ALL minimumAge: 20 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Taichung Veterans General Hospital status: RECRUITING city: Taichung zip: 40705 country: Taiwan name: Pin-Kuei Fu, MD, PhD role: CONTACT phone: 886-4-23592525 phoneExt: 3213 email: yetquen@gmail.com lat: 24.1469 lon: 120.6839 hasResults: False
nctId: NCT06280430 id: Vascular affection in behcet briefTitle: Vascular Affection in Behcet Disease overallStatus: NOT_YET_RECRUITING date: 2024-03-01 date: 2025-03-01 date: 2025-04-01 date: 2024-02-28 date: 2024-02-28 name: Assiut University class: OTHER briefSummary: To measure the level of serum elafin in patients with behcet disease and to assess the correlation between serum elafin and vascular affection and their relation with disease activity conditions: Behcet Disease and Vascular Involvement studyType: OBSERVATIONAL observationalModel: CASE_CONTROL timePerspective: RETROSPECTIVE count: 90 type: ESTIMATED measure: To measure the level of serum elafin in behcet patients and compare it with control group sex: ALL minimumAge: 20 Years maximumAge: 45 Years stdAges: ADULT hasResults: False
nctId: NCT06280417 id: Unreamed IMN In IIIa tibia briefTitle: Unreamed Intramedullary Tibial Nailing in Treatment of Open IIIa Diaphyseal Tibial Fractures in Adults overallStatus: NOT_YET_RECRUITING date: 2024-06-01 date: 2025-06-01 date: 2025-08-01 date: 2024-02-28 date: 2024-02-28 name: Assiut University class: OTHER briefSummary: To study the incidence of non union of Unreamed intramedullary nailing in type IIIa Open diaphyseal fractures of the tibia as a primary outcome and the incidence of complications and clinical and functional outcome as a secondary outcome . conditions: Tibia Fracture studyType: OBSERVATIONAL observationalModel: CASE_ONLY timePerspective: PROSPECTIVE count: 25 type: ESTIMATED name: Unreamed intramedullary tibial nail measure: Incidence of non union measure: Incidince of fracture related infection measure: The rate of reoperation for delayed union or non-union , infection and fasciotomy measure: functional evaluation sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
nctId: NCT06280404 id: Body first in lap chole briefTitle: Body First Approach in Lap Cholecystectomy in Cases With Obscure Calot's Triangle overallStatus: NOT_YET_RECRUITING date: 2024-03-15 date: 2025-03-15 date: 2025-08-08 date: 2024-02-28 date: 2024-02-28 name: Assiut University class: OTHER briefSummary: The aim of this study is to evaluate the body first approach on the rate of conversion to open technique \& VBI in patients with obscure calot's triangle. conditions: Cholecystitis, Chronic studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: PROSPECTIVE count: 30 type: ESTIMATED name: Lap cholecystectomy measure: Safe laparoscopic cholecystectomy. measure: Evaluation of the body first approach technique sex: ALL minimumAge: 18 Years maximumAge: 75 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
nctId: NCT06280391 id: ACT18018 id: U1111-1295-3237 type: REGISTRY domain: ICTRP id: 2023-508663-70 type: REGISTRY domain: CTIS briefTitle: A Proof-of-Concept Study to Assess the Efficacy, Safety and Tolerability of Itepekimab (Anti-IL-33 mAb) in Participants With Non-cystic Fibrosis Bronchiectasis overallStatus: RECRUITING date: 2024-02-20 date: 2026-03-24 date: 2026-08-11 date: 2024-02-28 date: 2024-04-12 name: Sanofi class: INDUSTRY name: Regeneron Pharmaceuticals briefSummary: ACT18018 is a multinational, randomized, double-blind, placebo-controlled, parallel-group, Phase 2 study with 3 treatment groups. The purpose of this study is to evaluate efficacy, safety and tolerability with 2 dosing regimens of itepekimab compared with placebo in male and/or female participants with NCFB aged 18 years of age up to 85 years of age (inclusive).